Tilray Brands(NASDAQ) TLRY

Tilray makes cannabis products for medical patients and adults. The company also sells craft beers and hemp-based wellness foods. These products reach people across North America, Europe, and Australia.

From Cannabis to Craft Beer

• Distribution Business: Purchases and resells pharmaceutical products to hospitals and pharmacies; accounts for 40% of revenue.
• Cannabis Business: Produces medical and adult-use products including flowers, oils, and edibles; represents 31% of revenue.
• Beverage Alcohol Business: Produces craft beers and spirits under brands like SweetWater and Breckenridge Distillery; makes up 21% of revenue.
• Wellness Business: Offers hemp-based foods and supplements for health-conscious consumers; contributes 8% of revenue.

Deals and Diversification

• Acquired four craft beer brands from Molson Coors Beverage Company on September 1, 2024, to expand its beverage segment.
• Completed the purchase of BrewDog plc on March 2, 2026, using $44.9 million held in restricted cash.
• Converted a facility in Quebec from vegetable production to cannabis cultivation during the nine months ended February 28, 2026.
• Implemented a one-for-ten reverse stock split for all outstanding common shares on December 2, 2025.

More Than Just Plants

Tilray maintains a presence in multiple industries by combining cannabis production with a large distribution network for European pharmaceuticals. The company uses its craft beer and hemp food divisions to build consumer brands in markets where cannabis sales remain restricted.

The Recent Financial Performance

• Net revenue reached $206.7 million for the three months ended February 28, 2026, up 11% from the same period last year.
• Net loss narrowed to $25.2 million for the three months ended February 28, 2026, compared to a $793.5 million loss in the prior year.
• Operating loss improved to $26.4 million for the three months ended February 28, 2026, compared to a loss of $759.9 million a year earlier.
• Distribution segment revenue grew to $83 million for the three months ended February 28, 2026, a 35% increase year-over-year.
• Cash and cash equivalents totaled $204.6 million as of February 28, 2026, down from $221.7 million in May 2025.

Bottom Line

Tilray has evolved from a specialized cannabis grower into a diversified consumer brands company. By expanding into alcohol and pharmaceuticals, it has reduced its reliance on the timing of global cannabis legalization.